Top-News
Biotechnologie USA

Dynavax Technologies News

Aktie
WKN:  A12EV9 ISIN:  US2681582019 US-Symbol:  DVAX
10,615 €
-0,29 €
-2,66%
30.04.24 20:07:44
Handeln Depot/Watchlist
Aktienanzahl *
128,47 Mio.
Marktkapitalisierung *
1,40 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 02.08.2023

Dynavax Technologies News

24.04.24 - PR Newswire
Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 PR Newswire
27.02.24 - PR Newswire
Dynavax to Present at TD Cowen's 44th Annual Health Care Conference
Dynavax to Present at TD Cowen's 44th Annual Health Care Conference PR Newswire
22.02.24 - PR Newswire
Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance
Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance PR Newswire
08.02.24 - PR Newswire
Dynavax to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 22, 2024
Dynavax to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 22, 2024 PR Newswire
08.01.24 - PR Newswire
Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Highlights
Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Highlights PR Newswire
03.01.24 - PR Newswire
Dynavax to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Dynavax to Present at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire
20.11.23 - PR Newswire
Dynavax to Present at the 6th Annual Evercore ISI HealthCONx Conference
Dynavax to Present at the 6th Annual Evercore ISI HealthCONx Conference PR Newswire
02.11.23 - PR Newswire
Dynavax Reports Third Quarter 2023 Financial Results and Raises Full Year Revenue Guidance
Dynavax Reports Third Quarter 2023 Financial Results and Raises Full Year Revenue Guidance PR Newswire
26.10.23 - PR Newswire
Dynavax to Report Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023
Dynavax to Report Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023 PR Newswire
19.10.23 - PR Newswire
Dynavax to Present at the H.C. Wainwright 4th Annual Hepatitis B Virus Virtual Conference
Dynavax to Present at the H.C. Wainwright 4th Annual Hepatitis B Virus Virtual Conference PR Newswire
06.09.23 - PR Newswire
Dynavax to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Dynavax to Present at the H.C. Wainwright 25th Annual Global Investment Conference PR Newswire
03.08.23 - PR Newswire
Dynavax Reports Second Quarter 2023 Financial Results and Raises Full Year Revenue Guidance
Dynavax Reports Second Quarter 2023 Financial Results and Raises Full Year Revenue Guidance PR Newswire
20.07.23 - PR Newswire
Dynavax to Report Second Quarter 2023 Financial Results and Host Conference Call on August 3, 2023
Dynavax to Report Second Quarter 2023 Financial Results and Host Conference Call on August 3, 2023 PR Newswire
30.05.23 - PR Newswire
Dynavax to Present at Upcoming Investor Conferences
Dynavax to Present at Upcoming Investor Conferences PR Newswire
08.05.23 - PR Newswire
Dynavax to Present at the JMP Securities Life Sciences Conference
Dynavax to Present at the JMP Securities Life Sciences Conference PR Newswire
02.05.23 - PR Newswire
Dynavax Reports First Quarter 2023 Financial Results
Dynavax Reports First Quarter 2023 Financial Results PR Newswire
18.04.23 - PR Newswire
Dynavax to Report First Quarter 2023 Financial Results and Host Conference Call on May 2, 2023
Dynavax to Report First Quarter 2023 Financial Results and Host Conference Call on May 2, 2023 PR Newswire
01.03.23 - PR Newswire
Dynavax to Present at the Cowen 43rd Annual Health Care Conference
Dynavax to Present at the Cowen 43rd Annual Health Care Conference PR Newswire
28.02.23 - PR Newswire
Dynavax Announces Great Britain Marketing Authorization for HEPLISAV B®, a Two-Dose Adult Hepatitis B Adjuvanted Vaccine
Dynavax Announces Great Britain Marketing Authorization for HEPLISAV B®, a Two-Dose Adult Hepatitis B Adjuvanted Vaccine PR Newswire
23.02.23 - PR Newswire
Dynavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Financial Guidance
Dynavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Financial Guidance PR Newswire

Newssuche

Videos

newspaper
03.05.24 -13,45%
Technical Trading: Gold freitags Long
Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »